newest glp-1 drugs Comparing Ozempic, Wegovy and Other Study predicts 16 new obesity

PMID: 13 Pi-SunyerXAstrupAFujiokaKGreenwayFHalpernAKrempfMet al

Up to 40% of the weight loss associated with using semaglutide is actually lean body mass, which is bad because you dont want to lose that, Parker said

These medications are powerful tools, but they are not right for everyone

For individuals with pre-existing gastrointestinal conditions such as inflammatory bowel disease, previous bowel surgery, or chronic constipation, closer monitoring may be warranted when initiating therapy

The leaders of tomorrow recognize the complexity of obesity not just as a disease, but as a multifactorial challenge requiring integrated, interdisciplinary solutions

doi: 10.3233/JAD-210256 [DOI] [PubMed] [Google Scholar] 236